ID   SDHA_HUMAN              Reviewed;         664 AA.
AC   P31040; A8K5J6; B4DJ60; E9PBJ5; Q16395; Q59GW8; Q8IW48; Q9UMY5;
DT   01-JUL-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 2.
DT   28-JAN-2026, entry version 250.
DE   RecName: Full=Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial;
DE            EC=1.3.5.1 {ECO:0000269|PubMed:10746566, ECO:0000305|PubMed:24781757};
DE   AltName: Full=Flavoprotein subunit of complex II;
DE            Short=Fp;
DE   AltName: Full=Malate dehydrogenase [quinone] flavoprotein subunit;
DE            EC=1.1.5.- {ECO:0000250|UniProtKB:P31039};
DE   Flags: Precursor;
GN   Name=SDHA; Synonyms=SDH2, SDHF;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=7798181; DOI=10.1093/oxfordjournals.jbchem.a124497;
RA   Hirawake H., Wang H., Kuramochi T., Kojima S., Kita K.;
RT   "Human complex II (succinate-ubiquinone oxidoreductase): cDNA cloning of
RT   the flavoprotein (Fp) subunit of liver mitochondria.";
RL   J. Biochem. 116:221-227(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS PHE-629 AND ILE-657.
RC   TISSUE=Heart;
RX   PubMed=8142412; DOI=10.1016/0005-2728(94)90203-8;
RA   Morris A.A.M., Farnsworth L., Ackrell B.A.C., Turnbull D.M.,
RA   Birch-MacHin M.A.;
RT   "The cDNA sequence of the flavoprotein subunit of human heart succinate
RT   dehydrogenase.";
RL   Biochim. Biophys. Acta 1185:125-128(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, CATALYTIC ACTIVITY, AND
RP   VARIANT LS VAL-524.
RX   PubMed=10746566; DOI=10.1007/s004390051033;
RA   Parfait B., Chretien D., Roetig A., Marsac C., Munnich A., Rustin P.;
RT   "Compound heterozygous mutations in the flavoprotein gene of the
RT   respiratory chain complex II in a patient with Leigh syndrome.";
RL   Hum. Genet. 106:236-243(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   VAL-38.
RC   TISSUE=Substantia nigra, and Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT PHE-629.
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RT   "Homo sapiens protein coding cDNA.";
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A.,
RA   Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R.,
RA   Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L.,
RA   Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N.,
RA   Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J.,
RA   Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A.,
RA   Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3), AND VARIANT
RP   PHE-629.
RC   TISSUE=Colon, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   PRELIMINARY PARTIAL NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Placenta;
RA   Malcovati M., Marchetti L., Zanelli E., Tenchini M.L.;
RT   "Cloning of the flavoprotein subunit of human succinate dehydrogenase.";
RL   (In) Curti B., Ronchi S., Zanetti G. (eds.);
RL   Flavins and flavoproteins 1990, pp.727-730, Walter de Gruyter, Berlin
RL   (1991).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 546-562, AND VARIANT LS TRP-554.
RX   PubMed=7550341; DOI=10.1038/ng1095-144;
RA   Bourgeron T., Rustin P., Chretien D., Birch-MacHin M.A., Bourgeois M.,
RA   Viegas-Pequignot E., Munnich A., Roetig A.;
RT   "Mutation of a nuclear succinate dehydrogenase gene results in
RT   mitochondrial respiratory chain deficiency.";
RL   Nat. Genet. 11:144-149(1995).
RN   [11]
RP   PROTEIN SEQUENCE OF 76-92 AND 398-418.
RC   TISSUE=Adipocyte;
RX   PubMed=15242332; DOI=10.1042/bj20040647;
RA   Aboulaich N., Vainonen J.P., Stralfors P., Vener A.V.;
RT   "Vectorial proteomics reveal targeting, phosphorylation and specific
RT   fragmentation of polymerase I and transcript release factor (PTRF) at the
RT   surface of caveolae in human adipocytes.";
RL   Biochem. J. 383:237-248(2004).
RN   [12]
RP   INTERACTION WITH SDHAF2.
RX   PubMed=19628817; DOI=10.1126/science.1175689;
RA   Hao H.-X., Khalimonchuk O., Schraders M., Dephoure N., Bayley J.-P.,
RA   Kunst H., Devilee P., Cremers C.W.R.J., Schiffman J.D., Bentz B.G.,
RA   Gygi S.P., Winge D.R., Kremer H., Rutter J.;
RT   "SDH5, a gene required for flavination of succinate dehydrogenase, is
RT   mutated in paraganglioma.";
RL   Science 325:1139-1142(2009).
RN   [13]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-179; LYS-335; LYS-541 AND
RP   LYS-608, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [14]
RP   FUNCTION, VARIANT PPGL5 TRP-589, AND CHARACTERIZATION OF VARIANT PPGL5
RP   TRP-589.
RX   PubMed=20484225; DOI=10.1093/hmg/ddq206;
RA   Burnichon N., Briere J.J., Libe R., Vescovo L., Riviere J., Tissier F.,
RA   Jouanno E., Jeunemaitre X., Benit P., Tzagoloff A., Rustin P.,
RA   Bertherat J., Favier J., Gimenez-Roqueplo A.P.;
RT   "SDHA is a tumor suppressor gene causing paraganglioma.";
RL   Hum. Mol. Genet. 19:3011-3020(2010).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [16]
RP   PHOSPHORYLATION AT TYR-215 BY SRC.
RX   PubMed=22823520; DOI=10.1042/bj20120509;
RA   Ogura M., Yamaki J., Homma M.K., Homma Y.;
RT   "Mitochondrial c-Src regulates cell survival through phosphorylation of
RT   respiratory chain components.";
RL   Biochem. J. 447:281-289(2012).
RN   [17]
RP   INTERACTION WITH TRAP1.
RX   PubMed=23747254; DOI=10.1016/j.cmet.2013.04.019;
RA   Sciacovelli M., Guzzo G., Morello V., Frezza C., Zheng L., Nannini N.,
RA   Calabrese F., Laudiero G., Esposito F., Landriscina M., Defilippi P.,
RA   Bernardi P., Rasola A.;
RT   "The mitochondrial chaperone TRAP1 promotes neoplastic growth by inhibiting
RT   succinate dehydrogenase.";
RL   Cell Metab. 17:988-999(2013).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [20]
RP   INTERACTION WITH LACC1.
RX   PubMed=28593945; DOI=10.1038/ncomms15614;
RA   Lahiri A., Hedl M., Yan J., Abraham C.;
RT   "Human LACC1 increases innate receptor-induced responses and a LACC1
RT   disease-risk variant modulates these outcomes.";
RL   Nat. Commun. 8:15614-15614(2017).
RN   [21] {ECO:0007744|PDB:6VAX}
RP   X-RAY CRYSTALLOGRAPHY (2.59 ANGSTROMS) OF 44-664 IN COMPLEX WITH SDHAF2;
RP   FAD AND OXALOACETATE, COFACTOR, AND INTERACTION WITH SDHAF2.
RX   PubMed=32887801; DOI=10.1073/pnas.2007391117;
RA   Sharma P., Maklashina E., Cecchini G., Iverson T.M.;
RT   "The roles of SDHAF2 and dicarboxylate in covalent flavinylation of SDHA,
RT   the human complex II flavoprotein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 117:23548-23556(2020).
RN   [22] {ECO:0007744|PDB:8GS8}
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.86 ANGSTROMS) IN COMPLEX WITH FAD,
RP   COFACTOR, SUBUNIT, AND SUBCELLULAR LOCATION.
RX   PubMed=37098072; DOI=10.1073/pnas.2216713120;
RA   Du Z., Zhou X., Lai Y., Xu J., Zhang Y., Zhou S., Feng Z., Yu L., Tang Y.,
RA   Wang W., Yu L., Tian C., Ran T., Chen H., Guddat L.W., Liu F., Gao Y.,
RA   Rao Z., Gong H.;
RT   "Structure of the human respiratory complex II.";
RL   Proc. Natl. Acad. Sci. U.S.A. 120:e2216713120-e2216713120(2023).
RN   [23]
RP   INVOLVEMENT IN NDAXOA, AND VARIANT NDAXOA CYS-451.
RX   PubMed=10976639;
RX   DOI=10.1002/1531-8249(200009)48:3<330::aid-ana7>3.3.co;2-1;
RA   Birch-Machin M.A., Taylor R.W., Cochran B., Ackrell B.A., Turnbull D.M.;
RT   "Late-onset optic atrophy, ataxia, and myopathy associated with a mutation
RT   of a complex II gene.";
RL   Ann. Neurol. 48:330-335(2000).
RN   [24]
RP   VARIANT MC2DN1 GLU-555.
RX   PubMed=12794685; DOI=10.1002/ajmg.a.10202;
RA   Van Coster R., Seneca S., Smet J., Van Hecke R., Gerlo E., Devreese B.,
RA   Van Beeumen J., Leroy J.G., De Meirleir L., Lissens W.;
RT   "Homozygous Gly555Glu mutation in the nuclear-encoded 70 kDa flavoprotein
RT   gene causes instability of the respiratory chain complex II.";
RL   Am. J. Med. Genet. A 120:13-18(2003).
RN   [25]
RP   VARIANT CMD1GG GLU-555.
RX   PubMed=20551992; DOI=10.1038/ejhg.2010.83;
RA   Levitas A., Muhammad E., Harel G., Saada A., Caspi V.C., Manor E.,
RA   Beck J.C., Sheffield V., Parvari R.;
RT   "Familial neonatal isolated cardiomyopathy caused by a mutation in the
RT   flavoprotein subunit of succinate dehydrogenase.";
RL   Eur. J. Hum. Genet. 18:1160-1165(2010).
RN   [26]
RP   VARIANT LS GLY-189, CHARACTERIZATION OF VARIANT LS GLY-189, FUNCTION,
RP   CATALYTIC ACTIVITY, AND PATHWAY.
RX   PubMed=24781757; DOI=10.1038/ejhg.2014.80;
RA   Renkema G.H., Wortmann S.B., Smeets R.J., Venselaar H., Antoine M.,
RA   Visser G., Ben-Omran T., van den Heuvel L.P., Timmers H.J., Smeitink J.A.,
RA   Rodenburg R.J.;
RT   "SDHA mutations causing a multisystem mitochondrial disease: novel
RT   mutations and genetic overlap with hereditary tumors.";
RL   Eur. J. Hum. Genet. 23:202-209(2015).
RN   [27]
RP   VARIANT ILE-508, AND VARIANT MC2DN1 LEU-509.
RX   PubMed=22972948; DOI=10.1136/jmedgenet-2012-101146;
RA   Alston C.L., Davison J.E., Meloni F., van der Westhuizen F.H., He L.,
RA   Hornig-Do H.T., Peet A.C., Gissen P., Goffrini P., Ferrero I., Wassmer E.,
RA   McFarland R., Taylor R.W.;
RT   "Recessive germline SDHA and SDHB mutations causing leukodystrophy and
RT   isolated mitochondrial complex II deficiency.";
RL   J. Med. Genet. 49:569-577(2012).
RN   [28]
RP   VARIANT ILE-508, AND VARIANT MC2DN1 LEU-509.
RX   PubMed=26642834; DOI=10.1002/ana.24572;
RG   SDH Study Group;
RA   Helman G., Caldovic L., Whitehead M.T., Simons C., Brockmann K.,
RA   Edvardson S., Bai R., Moroni I., Taylor J.M., Van Haren K., Taft R.J.,
RA   Vanderver A., van der Knaap M.S.;
RT   "Magnetic resonance imaging spectrum of succinate dehydrogenase-related
RT   infantile leukoencephalopathy.";
RL   Ann. Neurol. 79:379-386(2016).
RN   [29]
RP   VARIANT NDAXOA CYS-451.
RX   PubMed=27683074; DOI=10.1002/ajmg.a.37986;
RA   Courage C., Jackson C.B., Hahn D., Euro L., Nuoffer J.M., Gallati S.,
RA   Schaller A.;
RT   "SDHA mutation with dominant transmission results in complex II deficiency
RT   with ocular, cardiac, and neurologic involvement.";
RL   Am. J. Med. Genet. A 173:225-230(2017).
CC   -!- FUNCTION: Flavoprotein (FP) subunit of succinate dehydrogenase (SDH)
CC       that is involved in complex II of the mitochondrial electron transport
CC       chain and is responsible for transferring electrons from succinate to
CC       ubiquinone (coenzyme Q) (PubMed:10746566, PubMed:24781757). SDH also
CC       oxidizes malate to the non-canonical enol form of oxaloacetate, enol-
CC       oxaloacetate (By similarity). Enol-oxaloacetate, which is a potent
CC       inhibitor of the succinate dehydrogenase activity, is further
CC       isomerized into keto-oxaloacetate (By similarity). Can act as a tumor
CC       suppressor (PubMed:20484225). {ECO:0000250|UniProtKB:P31039,
CC       ECO:0000269|PubMed:10746566, ECO:0000269|PubMed:20484225,
CC       ECO:0000269|PubMed:24781757}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a ubiquinone + succinate = a ubiquinol + fumarate;
CC         Xref=Rhea:RHEA:13713, Rhea:RHEA-COMP:9565, Rhea:RHEA-COMP:9566,
CC         ChEBI:CHEBI:16389, ChEBI:CHEBI:17976, ChEBI:CHEBI:29806,
CC         ChEBI:CHEBI:30031; EC=1.3.5.1; Evidence={ECO:0000269|PubMed:10746566,
CC         ECO:0000305|PubMed:24781757};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(R)-malate + a quinone = enol-oxaloacetate + a quinol;
CC         Xref=Rhea:RHEA:79827, ChEBI:CHEBI:15588, ChEBI:CHEBI:17479,
CC         ChEBI:CHEBI:24646, ChEBI:CHEBI:132124;
CC         Evidence={ECO:0000250|UniProtKB:P31039};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:79828;
CC         Evidence={ECO:0000250|UniProtKB:P31039};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(S)-malate + a quinone = enol-oxaloacetate + a quinol;
CC         Xref=Rhea:RHEA:79831, ChEBI:CHEBI:15589, ChEBI:CHEBI:17479,
CC         ChEBI:CHEBI:24646, ChEBI:CHEBI:132124;
CC         Evidence={ECO:0000250|UniProtKB:P31039};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:79832;
CC         Evidence={ECO:0000250|UniProtKB:P31039};
CC   -!- COFACTOR:
CC       Name=FAD; Xref=ChEBI:CHEBI:57692;
CC         Evidence={ECO:0000269|PubMed:32887801, ECO:0000269|PubMed:37098072};
CC   -!- ACTIVITY REGULATION: Enol-oxaloacetate inhibits the succinate
CC       dehydrogenase activity. {ECO:0000250|UniProtKB:P31039}.
CC   -!- PATHWAY: Carbohydrate metabolism; tricarboxylic acid cycle; fumarate
CC       from succinate (eukaryal route): step 1/1.
CC       {ECO:0000305|PubMed:24781757}.
CC   -!- SUBUNIT: Component of complex II composed of four subunits: the
CC       flavoprotein (FP) SDHA, iron-sulfur protein (IP) SDHB, and a cytochrome
CC       b560 composed of SDHC and SDHD (PubMed:37098072). Interacts with
CC       SDHAF2/SDH5; interaction is required for FAD attachment
CC       (PubMed:19628817, PubMed:32887801). Interacts with TRAP1
CC       (PubMed:23747254). Interacts with LACC1 (PubMed:28593945).
CC       {ECO:0000269|PubMed:19628817, ECO:0000269|PubMed:23747254,
CC       ECO:0000269|PubMed:28593945, ECO:0000269|PubMed:32887801,
CC       ECO:0000269|PubMed:37098072}.
CC   -!- INTERACTION:
CC       P31040; P13569: CFTR; NbExp=15; IntAct=EBI-1057265, EBI-349854;
CC       P31040; P01889: HLA-B; NbExp=2; IntAct=EBI-1057265, EBI-1046513;
CC       P31040; P26045: PTPN3; NbExp=2; IntAct=EBI-1057265, EBI-1047946;
CC       P31040; Q9NX18: SDHAF2; NbExp=5; IntAct=EBI-1057265, EBI-713250;
CC       P31040; P21912: SDHB; NbExp=11; IntAct=EBI-1057265, EBI-1056481;
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane
CC       {ECO:0000269|PubMed:37098072}; Peripheral membrane protein
CC       {ECO:0000269|PubMed:37098072}; Matrix side
CC       {ECO:0000269|PubMed:37098072}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P31040-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P31040-2; Sequence=VSP_055077;
CC       Name=3;
CC         IsoId=P31040-3; Sequence=VSP_055078;
CC   -!- PTM: Phosphorylation at Tyr-215 is important for efficient electron
CC       transfer in complex II and the prevention of ROS generation.
CC       {ECO:0000269|PubMed:22823520}.
CC   -!- PTM: Acetylated. Deacetylated by SIRT3. {ECO:0000250|UniProtKB:Q8K2B3}.
CC   -!- DISEASE: Mitochondrial complex II deficiency, nuclear type 1 (MC2DN1)
CC       [MIM:252011]: A disorder of the mitochondrial respiratory chain with
CC       heterogeneous clinical manifestations. Clinical features include
CC       psychomotor regression in infants, poor growth with lack of speech
CC       development, severe spastic quadriplegia, dystonia, progressive
CC       leukoencephalopathy, muscle weakness, exercise intolerance,
CC       cardiomyopathy. Some patients manifest Leigh syndrome or Kearns-Sayre
CC       syndrome. MC2DN1 inheritance is autosomal recessive.
CC       {ECO:0000269|PubMed:12794685, ECO:0000269|PubMed:22972948,
CC       ECO:0000269|PubMed:26642834}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Leigh syndrome (LS) [MIM:256000]: An early-onset progressive
CC       neurodegenerative disorder characterized by the presence of focal,
CC       bilateral lesions in one or more areas of the central nervous system
CC       including the brainstem, thalamus, basal ganglia, cerebellum and spinal
CC       cord. Clinical features depend on which areas of the central nervous
CC       system are involved and include subacute onset of psychomotor
CC       retardation, hypotonia, ataxia, weakness, vision loss, eye movement
CC       abnormalities, seizures, and dysphagia. {ECO:0000269|PubMed:10746566,
CC       ECO:0000269|PubMed:24781757, ECO:0000269|PubMed:7550341}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Cardiomyopathy, dilated, 1GG (CMD1GG) [MIM:613642]: A disorder
CC       characterized by ventricular dilation and impaired systolic function,
CC       resulting in congestive heart failure and arrhythmia. Patients are at
CC       risk of premature death. {ECO:0000269|PubMed:20551992}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Pheochromocytoma/paraganglioma syndrome 5 (PPGL5)
CC       [MIM:614165]: A form of pheochromocytoma/paraganglioma syndrome, a
CC       tumor predisposition syndrome characterized by the development of
CC       neuroendocrine tumors, usually in adulthood. Pheochromocytomas are
CC       catecholamine-producing tumors that arise from chromaffin cells in the
CC       adrenal medulla. Paragangliomas develop from sympathetic paraganglia in
CC       the thorax, abdomen, and pelvis, as well as from parasympathetic
CC       paraganglia in the head and neck. PPGL5 inheritance is autosomal
CC       dominant. {ECO:0000269|PubMed:20484225}. Note=The disease is caused by
CC       variants affecting the gene represented in this entry.
CC   -!- DISEASE: Neurodegeneration with ataxia and late-onset optic atrophy
CC       (NDAXOA) [MIM:619259]: An autosomal dominant disorder characterized by
CC       slowly progressive cerebellar and gait ataxia, optic atrophy, and
CC       myopathy or myalgia. Additional features can include cardiomyopathy,
CC       psychiatric disturbances, and peripheral sensory impairment. Disease
CC       onset is usually in mid-adulthood. {ECO:0000269|PubMed:10976639,
CC       ECO:0000269|PubMed:27683074}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the FAD-dependent oxidoreductase 2 family.
CC       FRD/SDH subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAD92228.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=CAA37886.1; Type=Miscellaneous discrepancy; Note=Differs extensively from that shown.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=TCA Cycle Gene Mutation Database;
CC       URL="https://databases.lovd.nl/shared/genes/SDHA";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D30648; BAA06332.1; -; mRNA.
DR   EMBL; L21936; AAA20683.1; -; mRNA.
DR   EMBL; AF171030; AAD51006.1; -; Genomic_DNA.
DR   EMBL; AF171017; AAD51006.1; JOINED; Genomic_DNA.
DR   EMBL; AF171018; AAD51006.1; JOINED; Genomic_DNA.
DR   EMBL; AF171019; AAD51006.1; JOINED; Genomic_DNA.
DR   EMBL; AF171020; AAD51006.1; JOINED; Genomic_DNA.
DR   EMBL; AF171021; AAD51006.1; JOINED; Genomic_DNA.
DR   EMBL; AF171022; AAD51006.1; JOINED; Genomic_DNA.
DR   EMBL; AF171023; AAD51006.1; JOINED; Genomic_DNA.
DR   EMBL; AF171024; AAD51006.1; JOINED; Genomic_DNA.
DR   EMBL; AF171025; AAD51006.1; JOINED; Genomic_DNA.
DR   EMBL; AF171026; AAD51006.1; JOINED; Genomic_DNA.
DR   EMBL; AF171027; AAD51006.1; JOINED; Genomic_DNA.
DR   EMBL; AF171028; AAD51006.1; JOINED; Genomic_DNA.
DR   EMBL; AF171029; AAD51006.1; JOINED; Genomic_DNA.
DR   EMBL; AK291311; BAF84000.1; -; mRNA.
DR   EMBL; AK295937; BAG58722.1; -; mRNA.
DR   EMBL; AB208991; BAD92228.1; ALT_INIT; mRNA.
DR   EMBL; AC021087; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471235; EAW50983.1; -; Genomic_DNA.
DR   EMBL; BC001380; AAH01380.1; -; mRNA.
DR   EMBL; BC041016; AAH41016.1; -; mRNA.
DR   EMBL; X53943; CAA37886.1; ALT_SEQ; mRNA.
DR   EMBL; S79641; AAB35332.1; -; Genomic_DNA.
DR   CCDS; CCDS3853.1; -. [P31040-1]
DR   CCDS; CCDS77992.1; -. [P31040-2]
DR   PIR; JX0336; JX0336.
DR   PIR; S21302; S21302.
DR   RefSeq; NP_001281261.1; NM_001294332.2. [P31040-2]
DR   RefSeq; NP_004159.2; NM_004168.4. [P31040-1]
DR   PDB; 6VAX; X-ray; 2.59 A; A/C=44-664.
DR   PDB; 8DYD; X-ray; 1.52 A; A=44-664.
DR   PDB; 8DYE; X-ray; 1.44 A; A=54-664.
DR   PDB; 8GS8; EM; 2.86 A; A=1-664.
DR   PDBsum; 6VAX; -.
DR   PDBsum; 8DYD; -.
DR   PDBsum; 8DYE; -.
DR   PDBsum; 8GS8; -.
DR   AlphaFoldDB; P31040; -.
DR   EMDB; EMD-34225; -.
DR   SMR; P31040; -.
DR   BioGRID; 112290; 426.
DR   ComplexPortal; CPX-561; Mitochondrial respiratory chain complex II.
DR   CORUM; P31040; -.
DR   DIP; DIP-45851N; -.
DR   FunCoup; P31040; 1492.
DR   IntAct; P31040; 247.
DR   MINT; P31040; -.
DR   STRING; 9606.ENSP00000264932; -.
DR   BindingDB; P31040; -.
DR   ChEMBL; CHEMBL5758; -.
DR   DrugBank; DB04141; 2-Hexyloxy-6-Hydroxymethyl-Tetrahydro-Pyran-3,4,5-Triol.
DR   DrugBank; DB04657; Carboxin.
DR   DrugBank; DB00139; Succinic acid.
DR   DrugBank; DB04795; Thenoyltrifluoroacetone.
DR   DrugBank; DB09270; Ubidecarenone.
DR   DrugBank; DB08689; Ubiquinone Q1.
DR   DrugCentral; P31040; -.
DR   TCDB; 3.D.10.1.7; the prokaryotic succinate dehydrogenase (sdh) family.
DR   GlyGen; P31040; 2 sites, 1 O-linked glycan (2 sites).
DR   iPTMnet; P31040; -.
DR   MetOSite; P31040; -.
DR   PhosphoSitePlus; P31040; -.
DR   SwissPalm; P31040; -.
DR   BioMuta; SDHA; -.
DR   DMDM; 1169337; -.
DR   REPRODUCTION-2DPAGE; IPI00305166; -.
DR   CPTAC; CPTAC-440; -.
DR   jPOST; P31040; -.
DR   MassIVE; P31040; -.
DR   PaxDb; 9606-ENSP00000264932; -.
DR   PeptideAtlas; P31040; -.
DR   ProteomicsDB; 19239; -.
DR   ProteomicsDB; 54758; -. [P31040-1]
DR   Pumba; P31040; -.
DR   TopDownProteomics; P31040-1; -. [P31040-1]
DR   Antibodypedia; 22208; 414 antibodies from 35 providers.
DR   DNASU; 6389; -.
DR   Ensembl; ENST00000264932.11; ENSP00000264932.6; ENSG00000073578.19. [P31040-1]
DR   Ensembl; ENST00000510361.5; ENSP00000427703.1; ENSG00000073578.19. [P31040-2]
DR   GeneID; 6389; -.
DR   KEGG; hsa:6389; -.
DR   MANE-Select; ENST00000264932.11; ENSP00000264932.6; NM_004168.4; NP_004159.2.
DR   UCSC; uc003jao.5; human. [P31040-1]
DR   AGR; HGNC:10680; -.
DR   CIViC; 6389; 1 evidence item across 3 molecular profiles.
DR   ClinPGx; PA35605; -.
DR   CTD; 6389; -.
DR   DisGeNET; 6389; -.
DR   GeneCards; SDHA; -.
DR   GeneReviews; SDHA; -.
DR   HGNC; HGNC:10680; SDHA.
DR   HPA; ENSG00000073578; Tissue enhanced (heart muscle, skeletal muscle).
DR   MalaCards; SDHA; -.
DR   MIM; 252011; phenotype.
DR   MIM; 256000; phenotype.
DR   MIM; 600857; gene.
DR   MIM; 613642; phenotype.
DR   MIM; 614165; phenotype.
DR   MIM; 619259; phenotype.
DR   OpenTargets; ENSG00000073578; -.
DR   Orphanet; 139411; Carney triad.
DR   Orphanet; 97286; Carney-Stratakis syndrome.
DR   Orphanet; 154; Familial isolated dilated cardiomyopathy.
DR   Orphanet; 44890; Gastrointestinal stromal tumor.
DR   Orphanet; 29072; Hereditary pheochromocytoma-paraganglioma.
DR   Orphanet; 3208; Isolated succinate-CoQ reductase deficiency.
DR   VEuPathDB; HostDB:ENSG00000073578; -.
DR   eggNOG; KOG2403; Eukaryota.
DR   GeneTree; ENSGT00910000144277; -.
DR   InParanoid; P31040; -.
DR   OMA; PTGIWRM; -.
DR   OrthoDB; 71672at2759; -.
DR   PAN-GO; P31040; 5 GO annotations based on evolutionary models.
DR   PhylomeDB; P31040; -.
DR   BioCyc; MetaCyc:ENSG00000073578-MONOMER; -.
DR   PathwayCommons; P31040; -.
DR   Reactome; R-HSA-611105; Respiratory electron transport.
DR   Reactome; R-HSA-71403; Citric acid cycle (TCA cycle).
DR   Reactome; R-HSA-9854311; Maturation of TCA enzymes and regulation of TCA cycle.
DR   SignaLink; P31040; -.
DR   SIGNOR; P31040; -.
DR   UniPathway; UPA00223; UER01006.
DR   Agora; ENSG00000073578; Agora Nominated Target for Alzheimer's Disease.
DR   BioGRID-ORCS; 6389; 240 hits in 1171 CRISPR screens.
DR   ChiTaRS; SDHA; human.
DR   GeneWiki; SDHA; -.
DR   GenomeRNAi; 6389; -.
DR   Pharos; P31040; Tbio.
DR   PRO; PR:P31040; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; P31040; protein.
DR   Bgee; ENSG00000073578; Expressed in apex of heart and 97 other cell types or tissues.
DR   ExpressionAtlas; P31040; baseline and differential.
DR   GO; GO:0005743; C:mitochondrial inner membrane; ISS:UniProtKB.
DR   GO; GO:0005759; C:mitochondrial matrix; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IDA:HPA.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0045273; C:respiratory chain complex II (succinate dehydrogenase); IDA:UniProtKB.
DR   GO; GO:0009055; F:electron transfer activity; IBA:GO_Central.
DR   GO; GO:0050660; F:flavin adenine dinucleotide binding; IBA:GO_Central.
DR   GO; GO:0008177; F:succinate dehydrogenase (quinone) activity; IMP:UniProtKB.
DR   GO; GO:0006121; P:mitochondrial electron transport, succinate to ubiquinone; IBA:GO_Central.
DR   GO; GO:0007399; P:nervous system development; IMP:UniProtKB.
DR   GO; GO:0042776; P:proton motive force-driven mitochondrial ATP synthesis; NAS:ComplexPortal.
DR   GO; GO:0022904; P:respiratory electron transport chain; IDA:UniProtKB.
DR   GO; GO:0006105; P:succinate metabolic process; IDA:UniProtKB.
DR   GO; GO:0006099; P:tricarboxylic acid cycle; TAS:UniProtKB.
DR   FunFam; 3.90.700.10:FF:000001; Mitochondrial succinate dehydrogenase flavoprotein subunit; 1.
DR   FunFam; 4.10.80.40:FF:000004; Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial; 1.
DR   FunFam; 3.50.50.60:FF:000482; Succinate dehydrogenase complex, subunit A, flavoprotein (Fp); 1.
DR   FunFam; 3.50.50.60:FF:001062; Succinate dehydrogenase complex, subunit A, flavoprotein (Fp); 1.
DR   FunFam; 1.20.58.100:FF:000001; Succinate dehydrogenase flavoprotein subunit (SdhA); 1.
DR   Gene3D; 3.50.50.60; FAD/NAD(P)-binding domain; 1.
DR   Gene3D; 1.20.58.100; Fumarate reductase/succinate dehydrogenase flavoprotein-like, C-terminal domain; 1.
DR   Gene3D; 4.10.80.40; succinate dehydrogenase protein domain; 1.
DR   Gene3D; 3.90.700.10; Succinate dehydrogenase/fumarate reductase flavoprotein, catalytic domain; 1.
DR   InterPro; IPR003953; FAD-dep_OxRdtase_2_FAD-bd.
DR   InterPro; IPR036188; FAD/NAD-bd_sf.
DR   InterPro; IPR003952; FRD_SDH_FAD_BS.
DR   InterPro; IPR037099; Fum_R/Succ_DH_flav-like_C_sf.
DR   InterPro; IPR015939; Fum_Rdtase/Succ_DH_flav-like_C.
DR   InterPro; IPR030664; SdhA/FrdA/AprA.
DR   InterPro; IPR027477; Succ_DH/fumarate_Rdtase_cat_sf.
DR   InterPro; IPR011281; Succ_DH_flav_su_fwd.
DR   InterPro; IPR014006; Succ_Dhase_FrdA_Gneg.
DR   NCBIfam; TIGR01816; sdhA_forward; 1.
DR   NCBIfam; TIGR01812; sdhA_frdA_Gneg; 1.
DR   PANTHER; PTHR11632; SUCCINATE DEHYDROGENASE 2 FLAVOPROTEIN SUBUNIT; 1.
DR   PANTHER; PTHR11632:SF51; SUCCINATE DEHYDROGENASE [UBIQUINONE] FLAVOPROTEIN SUBUNIT, MITOCHONDRIAL; 1.
DR   Pfam; PF00890; FAD_binding_2; 1.
DR   Pfam; PF02910; Succ_DH_flav_C; 1.
DR   PIRSF; PIRSF000171; SDHA_APRA_LASPO; 1.
DR   SUPFAM; SSF51905; FAD/NAD(P)-binding domain; 1.
DR   SUPFAM; SSF46977; Succinate dehydrogenase/fumarate reductase flavoprotein C-terminal domain; 1.
DR   SUPFAM; SSF56425; Succinate dehydrogenase/fumarate reductase flavoprotein, catalytic domain; 1.
DR   PROSITE; PS00504; FRD_SDH_FAD_BINDING; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Cardiomyopathy;
KW   Direct protein sequencing; Disease variant; Electron transport; FAD;
KW   Flavoprotein; Leigh syndrome; Membrane; Mitochondrion;
KW   Mitochondrion inner membrane; Neurodegeneration; Oxidoreductase;
KW   Phosphoprotein; Primary mitochondrial disease; Proteomics identification;
KW   Reference proteome; Transit peptide; Transport; Tricarboxylic acid cycle;
KW   Tumor suppressor.
FT   TRANSIT         1..42
FT                   /note="Mitochondrion"
FT                   /evidence="ECO:0000250|UniProtKB:Q0QF01"
FT   CHAIN           43..664
FT                   /note="Succinate dehydrogenase [ubiquinone] flavoprotein
FT                   subunit, mitochondrial"
FT                   /id="PRO_0000010335"
FT   ACT_SITE        340
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000250|UniProtKB:Q9YHT1"
FT   BINDING         69
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000269|PubMed:32887801,
FT                   ECO:0000269|PubMed:37098072, ECO:0007744|PDB:6VAX,
FT                   ECO:0007744|PDB:8GS8"
FT   BINDING         72
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000269|PubMed:32887801,
FT                   ECO:0007744|PDB:6VAX"
FT   BINDING         91
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000269|PubMed:37098072,
FT                   ECO:0007744|PDB:8GS8"
FT   BINDING         92
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000269|PubMed:37098072,
FT                   ECO:0007744|PDB:8GS8"
FT   BINDING         98
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000269|PubMed:37098072,
FT                   ECO:0007744|PDB:8GS8"
FT   BINDING         100
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000269|PubMed:32887801,
FT                   ECO:0000269|PubMed:37098072, ECO:0007744|PDB:6VAX,
FT                   ECO:0007744|PDB:8GS8"
FT   BINDING         105
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000269|PubMed:32887801,
FT                   ECO:0000269|PubMed:37098072, ECO:0007744|PDB:6VAX,
FT                   ECO:0007744|PDB:8GS8"
FT   BINDING         221
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000269|PubMed:32887801,
FT                   ECO:0000269|PubMed:37098072, ECO:0007744|PDB:6VAX,
FT                   ECO:0007744|PDB:8GS8"
FT   BINDING         275
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000269|PubMed:32887801,
FT                   ECO:0007744|PDB:6VAX"
FT   BINDING         296
FT                   /ligand="oxaloacetate"
FT                   /ligand_id="ChEBI:CHEBI:16452"
FT                   /evidence="ECO:0000269|PubMed:32887801,
FT                   ECO:0007744|PDB:6VAX"
FT   BINDING         340
FT                   /ligand="oxaloacetate"
FT                   /ligand_id="ChEBI:CHEBI:16452"
FT                   /evidence="ECO:0000269|PubMed:32887801,
FT                   ECO:0007744|PDB:6VAX"
FT   BINDING         407
FT                   /ligand="oxaloacetate"
FT                   /ligand_id="ChEBI:CHEBI:16452"
FT                   /evidence="ECO:0000269|PubMed:32887801,
FT                   ECO:0007744|PDB:6VAX"
FT   BINDING         440
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000269|PubMed:37098072,
FT                   ECO:0007744|PDB:6VAX, ECO:0007744|PDB:8DYD,
FT                   ECO:0007744|PDB:8DYE, ECO:0007744|PDB:8GS8"
FT   BINDING         451
FT                   /ligand="oxaloacetate"
FT                   /ligand_id="ChEBI:CHEBI:16452"
FT                   /evidence="ECO:0000269|PubMed:32887801,
FT                   ECO:0007744|PDB:6VAX"
FT   BINDING         454
FT                   /ligand="oxaloacetate"
FT                   /ligand_id="ChEBI:CHEBI:16452"
FT                   /evidence="ECO:0000269|PubMed:32887801,
FT                   ECO:0007744|PDB:6VAX"
FT   BINDING         456
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000269|PubMed:32887801,
FT                   ECO:0000269|PubMed:37098072, ECO:0007744|PDB:6VAX,
FT                   ECO:0007744|PDB:8GS8"
FT   BINDING         457
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000269|PubMed:32887801,
FT                   ECO:0000269|PubMed:37098072, ECO:0007744|PDB:6VAX,
FT                   ECO:0007744|PDB:8GS8"
FT   MOD_RES         99
FT                   /note="Tele-8alpha-FAD histidine"
FT                   /evidence="ECO:0000269|PubMed:32887801,
FT                   ECO:0000269|PubMed:37098072, ECO:0007744|PDB:6VAX,
FT                   ECO:0007744|PDB:8GS8"
FT   MOD_RES         167
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K2B3"
FT   MOD_RES         179
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         179
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K2B3"
FT   MOD_RES         182
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K2B3"
FT   MOD_RES         215
FT                   /note="Phosphotyrosine; by SRC"
FT                   /evidence="ECO:0000269|PubMed:22823520"
FT   MOD_RES         250
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K2B3"
FT   MOD_RES         250
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K2B3"
FT   MOD_RES         335
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         335
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K2B3"
FT   MOD_RES         480
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K2B3"
FT   MOD_RES         485
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K2B3"
FT   MOD_RES         485
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K2B3"
FT   MOD_RES         498
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K2B3"
FT   MOD_RES         498
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K2B3"
FT   MOD_RES         517
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K2B3"
FT   MOD_RES         538
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K2B3"
FT   MOD_RES         538
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K2B3"
FT   MOD_RES         541
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         547
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K2B3"
FT   MOD_RES         547
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K2B3"
FT   MOD_RES         550
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K2B3"
FT   MOD_RES         598
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K2B3"
FT   MOD_RES         608
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         615
FT                   /note="N6-succinyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K2B3"
FT   MOD_RES         624
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K2B3"
FT   MOD_RES         636
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K2B3"
FT   MOD_RES         647
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K2B3"
FT   VAR_SEQ         105..152
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_055077"
FT   VAR_SEQ         126..270
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_055078"
FT   VARIANT         33
FT                   /note="F -> V (in dbSNP:rs1061518)"
FT                   /id="VAR_049214"
FT   VARIANT         38
FT                   /note="D -> V (in dbSNP:rs34635677)"
FT                   /evidence="ECO:0000269|PubMed:14702039"
FT                   /id="VAR_049215"
FT   VARIANT         189
FT                   /note="C -> G (in LS; decrease in succinate dehydrogenase
FT                   activity)"
FT                   /evidence="ECO:0000269|PubMed:24781757"
FT                   /id="VAR_074022"
FT   VARIANT         240
FT                   /note="E -> Q (in dbSNP:rs1041946)"
FT                   /id="VAR_049216"
FT   VARIANT         333
FT                   /note="V -> I (in dbSNP:rs1062468)"
FT                   /id="VAR_059307"
FT   VARIANT         451
FT                   /note="R -> C (in NDAXOA; dbSNP:rs1553999752)"
FT                   /evidence="ECO:0000269|PubMed:10976639,
FT                   ECO:0000269|PubMed:27683074"
FT                   /id="VAR_085584"
FT   VARIANT         508
FT                   /note="T -> I (in dbSNP:rs151266052)"
FT                   /evidence="ECO:0000269|PubMed:22972948,
FT                   ECO:0000269|PubMed:26642834"
FT                   /id="VAR_085396"
FT   VARIANT         509
FT                   /note="S -> L (in MC2DN1; uncertain significance;
FT                   dbSNP:rs397514541)"
FT                   /evidence="ECO:0000269|PubMed:22972948,
FT                   ECO:0000269|PubMed:26642834"
FT                   /id="VAR_085397"
FT   VARIANT         524
FT                   /note="A -> V (in LS; dbSNP:rs137852767)"
FT                   /evidence="ECO:0000269|PubMed:10746566"
FT                   /id="VAR_016878"
FT   VARIANT         554
FT                   /note="R -> W (in LS; dbSNP:rs9809219)"
FT                   /evidence="ECO:0000269|PubMed:7550341"
FT                   /id="VAR_002449"
FT   VARIANT         555
FT                   /note="G -> E (in MC2DN1 and CMD1GG; dbSNP:rs137852768)"
FT                   /evidence="ECO:0000269|PubMed:12794685,
FT                   ECO:0000269|PubMed:20551992"
FT                   /id="VAR_016879"
FT   VARIANT         589
FT                   /note="R -> W (in PPGL5; loss of activity;
FT                   dbSNP:rs387906780)"
FT                   /evidence="ECO:0000269|PubMed:20484225"
FT                   /id="VAR_065975"
FT   VARIANT         629
FT                   /note="Y -> F (in dbSNP:rs6960)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:8142412, ECO:0000269|Ref.5"
FT                   /id="VAR_071037"
FT   VARIANT         657
FT                   /note="V -> I (in dbSNP:rs6962)"
FT                   /evidence="ECO:0000269|PubMed:8142412"
FT                   /id="VAR_049217"
FT   CONFLICT        356
FT                   /note="G -> D (in Ref. 3; AAD51006)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        398
FT                   /note="E -> D (in Ref. 3; AAD51006)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        591
FT                   /note="A -> T (in Ref. 3; AAD51006)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        596
FT                   /note="D -> G (in Ref. 3; AAD51006)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        600
FT                   /note="R -> Q (in Ref. 3; AAD51006)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        618
FT                   /note="F -> L (in Ref. 4; BAG58722)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        640
FT                   /note="E -> G (in Ref. 3; AAD51006)"
FT                   /evidence="ECO:0000305"
FT   HELIX           52..54
FT                   /evidence="ECO:0007829|PDB:8GS8"
FT   STRAND          57..67
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   HELIX           71..82
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   STRAND          87..93
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   HELIX           95..97
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   HELIX           99..102
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   STRAND          113..115
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   HELIX           119..129
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   TURN            130..132
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   HELIX           136..156
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   STRAND          166..168
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   STRAND          171..178
FT                   /evidence="ECO:0007829|PDB:8DYD"
FT   TURN            179..182
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   STRAND          185..190
FT                   /evidence="ECO:0007829|PDB:8DYD"
FT   HELIX           196..209
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   TURN            210..212
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   STRAND          214..217
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   STRAND          219..227
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   STRAND          230..238
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   TURN            239..241
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   STRAND          244..254
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   HELIX           260..262
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   STRAND          263..268
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   HELIX           275..282
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   STRAND          293..300
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   TURN            301..303
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   HELIX           310..313
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   STRAND          317..319
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   HELIX           327..330
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   TURN            332..334
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   HELIX           335..337
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   HELIX           340..352
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   TURN            358..361
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   STRAND          363..367
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   HELIX           373..379
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   HELIX           383..391
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   TURN            395..397
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   STRAND          400..409
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   STRAND          412..415
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   STRAND          419..425
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   STRAND          428..437
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   HELIX           439..441
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   STRAND          445..447
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   HELIX           456..474
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   TURN            486..489
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   HELIX           490..500
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   STRAND          503..507
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   HELIX           508..522
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   STRAND          523..525
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   HELIX           529..545
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   HELIX           546..548
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   STRAND          556..558
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   HELIX           560..584
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   STRAND          594..597
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   STRAND          610..612
FT                   /evidence="ECO:0007829|PDB:8GS8"
FT   HELIX           618..620
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   STRAND          624..631
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   TURN            632..635
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   STRAND          636..643
FT                   /evidence="ECO:0007829|PDB:8DYE"
FT   TURN            651..653
FT                   /evidence="ECO:0007829|PDB:8DYE"
SQ   SEQUENCE   664 AA;  72692 MW;  180B664E3FFD0B34 CRC64;
     MSGVRGLSRL LSARRLALAK AWPTVLQTGT RGFHFTVDGN KRASAKVSDS ISAQYPVVDH
     EFDAVVVGAG GAGLRAAFGL SEAGFNTACV TKLFPTRSHT VAAQGGINAA LGNMEEDNWR
     WHFYDTVKGS DWLGDQDAIH YMTEQAPAAV VELENYGMPF SRTEDGKIYQ RAFGGQSLKF
     GKGGQAHRCC CVADRTGHSL LHTLYGRSLR YDTSYFVEYF ALDLLMENGE CRGVIALCIE
     DGSIHRIRAK NTVVATGGYG RTYFSCTSAH TSTGDGTAMI TRAGLPCQDL EFVQFHPTGI
     YGAGCLITEG CRGEGGILIN SQGERFMERY APVAKDLASR DVVSRSMTLE IREGRGCGPE
     KDHVYLQLHH LPPEQLATRL PGISETAMIF AGVDVTKEPI PVLPTVHYNM GGIPTNYKGQ
     VLRHVNGQDQ IVPGLYACGE AACASVHGAN RLGANSLLDL VVFGRACALS IEESCRPGDK
     VPPIKPNAGE ESVMNLDKLR FADGSIRTSE LRLSMQKSMQ NHAAVFRVGS VLQEGCGKIS
     KLYGDLKHLK TFDRGMVWNT DLVETLELQN LMLCALQTIY GAEARKESRG AHAREDYKVR
     IDEYDYSKPI QGQQKKPFEE HWRKHTLSYV DVGTGKVTLE YRPVIDKTLN EADCATVPPA
     IRSY
//
